Abiraterone acetate was originally developed jointly by Cancer Research UK and BTG, and then transferred the global development right and listing right to Cougar biopharmaceutical company (now a subsidiary of Johnson & Johnson). Abiraterone acetate was first approved to market in the United States on April 28, 2011. Its trade name is zytiga, oral tablet, 250mg, combined with prednisone in the treatment of castration resistant prostate cancer (CRPC) in which docetaxel can not control disease progression.
Abiraterone acetate is an oral effective CYP17 inhibitor, which is metabolized into abiraterone in vivo. Abiraterone acetate is a precursor of abiraterone and a drug targeting androgen receptor signal pathway.
Abiraterone is a CYP17 inhibitor used in combination with prednisone to treat prostate cancer patients who have received docetaxel chemotherapy metastasis. Abiraterone acetate is a precursor drug chemicalbook, which can be transformed into abiraterone after entering the body. The latter is an androgen biosynthesis inhibitor, which exerts its curative effect by inhibiting the activity of CYP17 enzyme and androgen biosynthesis.